Grace Therapeutics: Assessing The Path Forward For GTx-104
Source: SeekingAlpha
2026-06-01 05:39:39 ET
EQUITY RESEARCH | SPECIALTY PHARMACEUTICALS
Grace Therapeutics, Inc. ( GRCE )
Initiating Coverage
Item | Value |
Rating | SPECULATIVE BUY |
Price Target | $4.00 (scenario-weighted) |
Current Price | $2.54 |
Implied Upside | +57% |
Strategy Bucket | Crisis Alpha, Event-Driven Post CRL |
Read the full article on Seeking Alpha
For further details see:
Grace Therapeutics: Assessing The Path Forward For GTx-104
Grace Therapeutics Inc.
NASDAQ: GRCE
GRCE Trading
-0.41% G/L:
$2.45 Last:
93,566 Volume:
$2.44 Open:
GRCE Latest News
June 18, 2026 08:00:00 am
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
May 27, 2026 11:33:00 am
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
April 23, 2026 01:13:24 pm
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
$50,750,823
10,912,118
1.33%
19
N/A
Biotechnology & Life Sciences
Healthcare
CA
Princeton
